|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||123.28 - 124.44|
|52 Week Range||121.28 - 148.32|
|PE Ratio (TTM)||262.11|
|Forward Dividend & Yield||3.36 (2.57%)|
|1y Target Est||N/A|
H ealth workers in Democratic Republic of Congo will begin a vaccination campaign on Monday aimed at containing an outbreak of the deadly Ebola virus, a spokeswoman for the health ministry said. Jessica Ilunga said 4,000 doses of vaccine were shipped on Saturday to Mbandaka, which last week registered the first cases in an urban area since the latest flare-up of the disease was announced earlier this month.
GENEVA/KINSHASA, May 18 (Reuters) - The Ebola outbreak in Democratic Republic of Congo can be brought under control and is not an international public health emergency, experts advising the World Health Organization said on Friday. Earlier in the day the WHO had said the first confirmation of Ebola in Mbandaka, a city of about 1.5 million people, had prompted it to declare a "very high" public health risk to the country and a "high" risk to the region.
Eli Lilly (LLY) reported EPS of $1.34 and revenues of $5.7 billion in the first quarter. Both results surpassed Wall Street analysts’ estimates.
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
Johnson and Johnson said it would stop mid-stage trials testing its experimental Alzheimer's drug after observing safety issues, the latest drugmaker to abandon developing treatments for the memory-robbing disease. Some trial participants showed serious elevations of liver enzymes and the company concluded that the benefit-risk ratio offered by the drug, atabecestat, no longer supported its development, said http://www.janssen.com/update-janssens-bace-inhibitor-program Janssen, a unit of Johnson and Johnson. Atabecestat belongs to a class of experimental Alzheimer's drugs called BACE inhibitors that block an enzyme involved in the production of a protein that creates brain plaques, which are considered a major cause for the disease.
As would-be parents push back parenthood and birth rates continue to decline companies that provide baby products are feeling the pinch.
Johnson & Johnson ( JNJ) shares may drop by about 10% based on an analysis of the technical chart. Should shares of the stock fall an additional 10%, it would mean Johnson and Johnson would have dropped by nearly 25% from its intraday high of around $148 on January 22. The technical setup continues to be negative in the stock, and it appears shares could fall from roughly $124.25 to about $111.33, a drop of 10.4%.
Many exchange-traded funds that are viewed as “core” holdings are cap-weighted. Core funds that emphasize individual investment factors usually focus on growth or value with quality often left out of the ...
The ability to sell new drugs hinges on approvals from government bodies such as the Food and Drug Administration (FDA). As a result, biotech companies, and to some degree, large drug companies, go into business ventures without the certainty of ever earning revenues, let alone profits. Biotech stocks often become some of the most difficult to evaluate.
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand the immunological basis of three common, serious inflammatory diseases—rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases—by making use of Verily’s Immunoscape platform.
Novartis (NVS) is one of the leading pharmaceutical companies worldwide. AveXis (AVXS) is a US-based clinical-stage gene therapy company. On May 15, Novartis announced that it completed the acquisition of AveXis.
Gilead Sciences (GILD) stock has corrected 9.6% since the start of 2018 to close at $66.99 on May 15. In comparison, Johnson & Johnson (JNJ), Pfizer (PFE), and Merck & Co. (MRK) have returned -9.5%, -2.1%, and 5.3%, respectively.
Jim Cramer said on CNBC's "Mad Money Lightning Round" he likes Johnson & Johnson (NYSE: JNJ ). Pure Storage Inc (NYSE: PSTG ) is a buy, thinks Cramer. He added that the company has a very smart ...
The New Brunswick, N.J.-based Johnson & Johnson’s Human Performance Institute is looking for more people to join its Lake Nona team.
Gilead Sciences (GILD) is a research-based biopharmaceutical company focused on discovering, developing, and bringing to market innovative medicines for life-threatening diseases. Gilead released its first-quarter earnings on May 4. Of the 26 analysts covering Gilead Sciences stock in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.2 with a target price of $85.81, which implies an upside potential of 27.2% over its closing price of $66.99 on May 15.
Pfizer's (PFE) Retacrit, a biosimilar of Amgen's Epogen and J&J's Procrit gets FDA approval. The drug will be available for the treatment of anemia.
"There are going to be changes in the pricing system" for prescription drugs, Johnson & Johnson chief Alex Gorsky acknowledges.
Let's check out the Yahoo Finance charts of the day. Macy's (M): Shares are up in early trade, around 7%. The department store reported earnings and sales that beat analysts' expectations, citing a healthier inventory position after the holiday season that prompted the company to hike its outlook for the full year. Johnson & Johnson (JNJ): Shares up slightly at .26%. The iconic brand is revamping its baby product line, putting more emphasis on natural ingredients. The company said it is confident that the move will reverse several years of declining sales of those products. T. Rowe Price (TROW): Shares rallying here, around 2.8%. The stock was upgraded to "outperform" from "neutral" at Credit Suisse, which sites rising organic growth as well as better expense control at the investment firm. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.